DUBLIN--(BUSINESS WIRE)--Aug 7, 2018--The "Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy" report has been added to ResearchAndMarkets.com's offering.

The key objectives of this study are to:

Review the historical development of CAR T-cell technology Discuss the principles of chimeric antigen receptor design Understand the mechanisms of action associated with CAR T-cell immunotherapy Highlight the ongoing clinical and non-clinical advancements in the field of CAR T-cell therapy Access the side effects, disadvantages and limitations of existing CAR T-cell technologies Examine the current marketed drugs, including development activities and details of patent expirations Determine the production methods for CAR T-cells Review the range of joint ventures, collaborations, license and research agreements currently focused on CAR T-cell technology Review of the regulatory requirements Review the global CAR T-cell therapy market dynamics Survey the key players involved in the development of therapeutics for CAR T-cell immunotherapy and provide company profiles

The report includes:

31 data tables and 41 additional tables An overview of the global market for current research & developments status of Chimeric Antigen Receptor (CAR) T-cell therapy Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023 Understand the market dynamics of CAR T-Cell therapy, along with the growth driving factors, restraints and future scope Information on competitor initiatives, research and development status of CAR T-cell therapy Comprehensive company profiles of major players in the market

Key Topics Covered

1 Introduction

2 Summary and Highlights

3 Introduction to Chimeric Antigen Receptor (CAR) T-Cell Therapy

4 Current Production Methods, Latest Technological Advances and Future Direction

5 Clinical Trial Analysis of CAR T-Cells and Related Technologies

6 Incidence, Prevalence and Mortality Statistics for Cancer: A Global Summary

7 Global CAR T-Cell Market Analysis

8 Regulatory and Legislative Requirements for CAR T-Cell and Related Technologies

9 Patent Review/New Developments for Chimeric Antigen Receptors (CARs)

10 Company Profiles

Amgen Avacta Life Sciences Ltd. Bellicum Phamaceuticals Bluebird Bio Celgene Corp. Cellectis Celyad SA Editas Medicine Inc. Eureka Therapeutics Inc. F. Hoffman La Roche AG Formula Pharmaceuticals Inc. Gilead Sciences iCell Gene Therapeutics Juno Therapeutics Inc. (A Celgene Company) Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.) Medimmune Llc/Astrazeneca Mustang Bio Inc. Noile-Immune Biotech Novartis AG Protheragen Inc. Puretech Health Servier Laboratories Shire Pharmaceuticals Inc. Takeda Pharmaceuticals Transgene SA

For more information about this report visit https://www.researchandmarkets.com/research/w7xjsd/current_research?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180807005543/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics,Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/07/2018 10:22 AM/DISC: 08/07/2018 10:22 AM